Full-Time

Principal Associate Scientist / Scientist

Immunology Discovery Research

Posted on 1/29/2025

Generation Bio

Generation Bio

51-200 employees

Develops durable genetic treatments for diseases

No salary listed

Mid, Senior

Cambridge, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Experience in the fields of immunology or cell biology (or related)
  • MS with a minimum of 3 years or BS with a minimum of 6 years of industry experience
  • Demonstrated hands-on experience in primary immune cell assay development and execution is required
  • Experience isolating and culturing primary T cells from human and/or mouse is essential
  • Ability to work cross functionally in a dynamic matrixed environment
  • Ability to multi-task to support multiple projects across platform discovery organization
  • Organized, excellent communication skills, collaborative mindset
Responsibilities
  • Contribute to the design, optimization and execution of assays to assess ctLNP interactions with primary immune cells
  • Generate target validation / proof of concept data packages using siRNA-mediated modulation of T cell targets
  • Work with Preclinical Group to screen novel ctLNPs and target biology for new platform technologies
  • Perform a range of biochemical techniques such as ELISA, MSD, qPCR and flow cytometry to characterize protein and RNA expression and function
  • Design experiments, analyze data and interpret results
  • Summarize work in written reports and oral presentations
  • Maintain accurate and up-to-date laboratory records
Desired Qualifications
  • Experience with T cell assays (such as T cell activation and differentiation) preferred
  • Knowledge of flow cytometry and multi-color panel design strongly desired
  • Experience with qPCR, western blot techniques, ELISAs, etc. a plus

Generation Bio focuses on developing long-lasting and repeatable genetic treatments for both rare and common diseases. The company utilizes a unique non-viral genetic medicine platform that includes iqDNA, which is designed to avoid triggering immune responses, and ctLNP, a delivery system that targets specific cells using lipid nanoparticles. Their manufacturing process, called rapid enzymatic synthesis (RES), allows for the efficient production of iqDNA, enabling the delivery of large amounts of genetic material to targeted tissues. This process not only aims to provide durable effects from a single treatment but also allows for adjustments in treatment through redosing. Generation Bio stands out from competitors by offering scalable production capabilities that can potentially yield hundreds of millions of doses, making genetic medicine more accessible. The company's goal is to address significant medical needs by developing effective genetic therapies for a wide range of diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic reorganization extends cash runway into 2027, supporting R&D efforts.
  • Focus on both rare and prevalent diseases broadens market potential.
  • Moderna collaboration highlights demand for non-viral delivery systems.

What critics are saying

  • 40% workforce reduction may cause operational challenges and project delays.
  • Lease termination could indicate potential legal or financial disputes.
  • Reliance on collaboration income suggests potential financial instability.

What makes Generation Bio unique

  • Generation Bio's iqDNA evades immune detection, unlike traditional viral vectors.
  • Their ctLNP system targets specific cells, enhancing delivery precision.
  • RES manufacturing allows scalable production, meeting large-scale demand efficiently.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

1%

2 year growth

7%
BioSpace
Feb 27th, 2025
Generation Bio To Present At The Td Cowen 45Th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event

BioSpace
Apr 2nd, 2024
Generation Bio To Present At The 23Rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.About Generation BioGeneration Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.For more information, please visit www.generationbio.com.Investors and Media Contact

TipRanks
Jan 31st, 2024
Generation Bio Co. Ends Lease Citing Landlord Breach

Generation Bio Co. ends lease citing landlord breach.

BioSpace
Nov 29th, 2023
Generation Bio Announces Strategic Reorganization To Extend Cash Runway For Development Of Ctlnp And Iqdna Platforms

Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell types. Development of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continueStrategic reorganization will result in a 40% reduction of workforce . Anticipated cost savings to extend cash runway into 2H 2027

Benzinga
Oct 18th, 2023
Generation Bio Announces Breakthrough In Its Non-Viral Genetic Medicine Platform With Novel "Immune-Quiet" Dna

Loading. Loading. Loading...– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA– Company is advancing iqDNA in lieu of prior ceDNA constructs across all programs, including its lead program in hemophilia A– Company is extending cash runway guidance into 2026 through collaboration income and expense control while increasing investment in its iqDNA and cell-targeted lipid nanoparticle (ctLNP) platforms– Company will present data on iqDNA and ctLNP platforms at upcoming scientific meetings today and on October 26, and will host a webcast R&D event on November 1CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. GBIO, a biotechnology company developing genetic medicines for people living with rare and prevalent diseases, today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an optimized variant of the company's closed-ended DNA (ceDNA) that upon systemic administration with Generation Bio's lipid nanoparticle (LNP) delivery has shown cytokine levels and tolerability comparable to chemically modified messenger RNA (mRNA) in mice and non-human primates (NHPs).Generation Bio's non-viral genetic medicine platform aims to advance durable, redosable, and titratable therapies to reach potentially hundreds of millions of patients worldwide

INACTIVE